Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID-19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety.
Keywords: COVID‐19; SARS‐CoV‐2; chronic kidney diseases (CKD); remdesivir.
© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.